Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Alpine Immune Sciences stock | $10.55

Own Alpine Immune Sciences stock in just a few minutes.

Fact checked

Alpine Immune Sciences, Inc is a biotechnology business based in the US. Alpine Immune Sciences shares (ALPN) are listed on the NASDAQ and all prices are listed in US Dollars. Alpine Immune Sciences employs 53 staff and has a trailing 12-month revenue of around USD$4.6 million.

How to buy shares in Alpine Immune Sciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Alpine Immune Sciences. Find the stock by name or ticker symbol: ALPN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alpine Immune Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$10.55, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alpine Immune Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Alpine Immune Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Alpine Immune Sciences share price

Use our graph to track the performance of ALPN stocks over time.

Alpine Immune Sciences shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$10.55
52-week rangeUSD$2.05 - USD$16.37
50-day moving average USD$10.5729
200-day moving average USD$9.1475
Wall St. target priceUSD$21.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.971

Buy Alpine Immune Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alpine Immune Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alpine Immune Sciences price performance over time

Historical closes compared with the close of $10.55 from 2020-12-09

1 week (2021-01-08) -21.50%
1 month (2020-12-16) -23.38%
3 months (2020-10-15) 20.43%
6 months (2020-07-15) 12.35%
1 year (2020-01-15) 154.22%
2 years (2019-01-15) 77.91%
3 years (2018-01-12) 11.01
5 years (2016-01-15) 83.48%

Alpine Immune Sciences financials

Revenue TTM USD$4.6 million
Gross profit TTM USD$-34,107,000
Return on assets TTM -16.74%
Return on equity TTM -54.23%
Profit margin 0%
Book value $2.834
Market capitalisation USD$378.5 million

TTM: trailing 12 months

Shorting Alpine Immune Sciences shares

There are currently 28,151 Alpine Immune Sciences shares held short by investors – that's known as Alpine Immune Sciences's "short interest". This figure is 4.6% up from 26,922 last month.

There are a few different ways that this level of interest in shorting Alpine Immune Sciences shares can be evaluated.

Alpine Immune Sciences's "short interest ratio" (SIR)

Alpine Immune Sciences's "short interest ratio" (SIR) is the quantity of Alpine Immune Sciences shares currently shorted divided by the average quantity of Alpine Immune Sciences shares traded daily (recently around 97072.413793103). Alpine Immune Sciences's SIR currently stands at 0.29. In other words for every 100,000 Alpine Immune Sciences shares traded daily on the market, roughly 290 shares are currently held short.

However Alpine Immune Sciences's short interest can also be evaluated against the total number of Alpine Immune Sciences shares, or, against the total number of tradable Alpine Immune Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alpine Immune Sciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Alpine Immune Sciences shares in existence, roughly 0 shares are currently held short) or 0.0027% of the tradable shares (for every 100,000 tradable Alpine Immune Sciences shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alpine Immune Sciences.

Find out more about how you can short Alpine Immune Sciences stock.

Alpine Immune Sciences share dividends

We're not expecting Alpine Immune Sciences to pay a dividend over the next 12 months.

Have Alpine Immune Sciences's shares ever split?

Alpine Immune Sciences's shares were split on a 1:4 basis on 25 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alpine Immune Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Alpine Immune Sciences shares which in turn could have impacted Alpine Immune Sciences's share price.

Alpine Immune Sciences share price volatility

Over the last 12 months, Alpine Immune Sciences's shares have ranged in value from as little as $2.05 up to $16.37. A popular way to gauge a stock's volatility is its "beta".

ALPN.US volatility(beta: 1.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alpine Immune Sciences's is 1.7065. This would suggest that Alpine Immune Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alpine Immune Sciences overview

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site